Strongbridge Biopharma plc (NASDAQ:SBBP) Q1 2020 Earnings Conference Call - Final Transcript

May 06, 2020 • 08:30 am ET

Previous

Strongbridge Biopharma plc (NASDAQ:SBBP) Q1 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good morning, ladies and gentlemen, and welcome to Strongbridge Biopharma's First Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions on how to participate will be given at that time. [Operator Instructions] As a reminder, today's conference call is being recorded.

Now, I would like to turn the conference over to your host, Lindsay Rocco of Elixir Health Public Relations.

Executive
Lindsay Rocco

Thank you and good morning everyone. We are pleased that you could join us for Strongbridge Biopharma's quarter 2020 earnings conference call. Joining me from Strongbridge, this morning, are John Johnson, Executive Chairman; Dr. Fred Cohen, Chief Medical Officer; and Rob Lutz, Chief Financial Officer.

Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission.

I will now turn the call over to John Johnson.

Executive
John H. Johnson

Thanks, Lindsay. Good morning, everyone. And thank you for joining us today. To begin, I would like to extend our organization's gratitude to the healthcare professionals and first responders, who are bravely serving on the front lines at such an unprecedented and challenging time. Our collective thoughts are also with the individuals and their loved ones who have been directly impacted by the COVID-19 global pandemic.

This pandemic has also posed many challenges in ensuring the continuum of care for many people living with chronic conditions including rare disease. Our team has been working tirelessly over the last several weeks to ensure minimal disruptions for the patient and physician communities that we serve.

Importantly, we are pleased to have an unaffected supply chain of our medicines, and we do not anticipate any shortages due to the global pandemic. The team's dedicated efforts guided by the impressive leadership of Fred Cohen, our Chief Medical Officer, most notably extends [Phonetic] the supporting our Phase 3 LOGICS study, which has continued to progress on track despite having sites in highly affected areas. This is in large part due to the ingenuity and commitment of the many stakeholders involved.

Today, we were delighted to announce that 41 of 42 targeted study participants have completed the randomized withdrawal phase of the Phase 3 LOGICS study. There is one additional patient currently in a randomized withdrawal phase and one other patient scheduled to be randomized imminently. Enrollment will close on or before May 14th.

We are incredibly pleased to reach this important milestone in our clinical development program for RECORLEV; a therapeutic candidate, which, if approved, we believe has the potential to play an important role in the treatment of endogenous Cushing's syndrome, given that the unmet medical needs remain very high for this